SCHEMBL3066281

SCHEMBL3066281

[CH2]c1cccc(S(=O)(=O)NCCCCCC)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.57
HTT P42858 2/20 0.57
MAPK1 P28482 1/20 0.57
ALDH1A1 P00352 7/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
KDM4E B2RXH2 1/20 0.54
PKM P14618 1/20 0.54
KMT2A Q03164 4/20 0.50
TSHR P16473 3/20 0.50
EPHX2 P34913 1/20 0.50
RECQL P46063 1/20 0.50
MEN1 O00255 3/20 0.49
TP53 P04637 2/20 0.49
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 2/20 0.49
CYP2C19 P33261 2/20 0.49
TDP1 Q9NUW8 1/20 0.49
PDK1 Q15118 1/20 0.46
PDK2 Q15119 1/20 0.46
PDK3 Q15120 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11704757 0.84 KMT2A (0.73) LMNAHTTMAPK1ALDH1A1SMN1; SMN2
SCHEMBL6151748 0.82 LMNA (0.57) LMNAHTTMAPK1ALDH1A1SMN1; SMN2
SCHEMBL6151749 0.82 PRMT1 (0.59) LMNAHTTMAPK1ALDH1A1SMN1; SMN2
SCHEMBL31014170 0.82 LMNA (0.56) LMNAHTTMAPK1ALDH1A1SMN1; SMN2
SCHEMBL11706540 0.82 KMT2A (0.76) LMNAHTTMAPK1ALDH1A1SMN1; SMN2
SCHEMBL5020960 0.81 ALDH1A1 (0.82) LMNAHTTMAPK1ALDH1A1SMN1; SMN2
SCHEMBL633906 0.81 ALDH1A1 (0.82) LMNAHTTMAPK1ALDH1A1SMN1; SMN2
SCHEMBL578832 0.81 ALDH1A1 (0.82) LMNAHTTMAPK1ALDH1A1SMN1; SMN2
SCHEMBL1279062 0.81 ALDH1A1 (0.82) LMNAHTTMAPK1ALDH1A1SMN1; SMN2
SCHEMBL579136 0.81 ALDH1A1 (0.82) LMNAHTTMAPK1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8551999-B2 Heterocyclic compound and pharmaceutical composition thereof OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-10-08 US disclosed
EP-2207773-B1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF OTSUKA PHARMA CO LTD (JP) 2012-07-11 EP disclosed
US-20100261720-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-10-14 US disclosed
EP-2207773-A2 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF Otsuka Pharmaceutical Co., Ltd. (JP) 2010-07-21 EP disclosed
WO-2009057811-A2 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261720-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF COL1A1, COL2A1, COL14A1 LMNA 1184/4885HTT 1225/4885MAPK1 3473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.